Related Experiment Video

Updated: Jun 24, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma

Shunya Ohmura1,2,3, Thomas G P Grünewald1,2,3,4

  • 1Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 11, 2024
PubMed

Insights

Pharmacologic ATR kinase inhibition synergizes with cisplatin to treat Ewing sarcoma by rewiring cellular machinery. This combination therapy offers a wider therapeutic window for treating this rare cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Ewing sarcoma is driven by the EWSR1::FLI1 fusion oncogene, which dysregulates cellular processes.
  • Targeting EWSR1::FLI1-mediated pathways presents a therapeutic opportunity.

Purpose of the Study:

  • To investigate the synergistic effects of ATR kinase inhibition and cisplatin in Ewing sarcoma.
  • To elucidate the molecular mechanisms underlying this synergy.

Main Methods:

  • Utilized pharmacologic ATR kinase inhibition in combination with low-dose cisplatin.
  • Analyzed EWSR1::FLI1-dependent alterations in transcription, DNA repair, and translation.

Main Results:

  • ATR kinase inhibition synergized with cisplatin, enhancing anti-cancer effects.
  • The combination therapy induced significant rewiring of cellular machinery dependent on EWSR1::FLI1.
  • This rewiring potentially broadens the therapeutic window for combination treatment.

Conclusions:

  • Pharmacologic ATR kinase inhibition combined with cisplatin shows promise for Ewing sarcoma treatment.
  • The EWSR1::FLI1-dependent rewiring of cellular processes is a key mechanism for this synergistic effect.
  • This approach may improve the therapeutic efficacy and safety of Ewing sarcoma treatment.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K